Patient Derived Xenografts (PDX) and Individualized Cancer Therapy
Genomic medicine offers the potential of improved outcomes for cancer patients by treating each individual with targeted therapies based on the genetic profile of their tumor. The Jackson Laboratory (JAX) has developed a platform for genomic and in vivo drug efficacy studies to advance the development of novel cancer therapies that are tailored to an individual patient. At the foundation of this platform are Patient Derived Xenografts (PDX) that are created by implanting human tumor material in immunodeficient NOD.Cg-Prkdcscid ll2rgtm1WjllSzJ (NOD scid gamma or NSG) mice. We have engrafted human tumors from over 20 different types of cancer into NSG mice to build a living tumor bank of over 350 Patient Derived Xenografts (PDX). Panels of PDX mice are ideally suited for “virtual clinical trials” to test experimental and existing therapies on a large scale and with high throughput. In this presentation I will describe the current state of the PDX resource and review the results of several Cancer Avatar platform validation studies, including the integration of PDX models with Phase ll/lll clinical trials in bladder and lung cancer.
Recommended CitationBult, PhD, Carol J., "Patient Derived Xenografts (PDX) and Individualized Cancer Therapy" (2014). RNA Matters Lecture Series. Presentation 11.